{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:25:43Z","timestamp":1787682343755,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA043204"],"award-info":[{"award-number":["DA043204"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA011792"],"award-info":[{"award-number":["DA011792"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA058666"],"award-info":[{"award-number":["DA058666"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA049886"],"award-info":[{"award-number":["DA049886"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA029023"],"award-info":[{"award-number":["AA029023"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03762-0","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:25:40Z","timestamp":1763727940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical evidence for a novel pharmacotherapeutic approach for treating benzodiazepine addiction"],"prefix":"10.1038","volume":"16","author":[{"given":"Lais F.","family":"Berro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseu C.","family":"Moreira-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Hembree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7087-4364","authenticated-orcid":false,"given":"Victoria L.","family":"Comfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2393-6824","authenticated-orcid":false,"given":"Daniela","family":"R\u00fcedi-Bettschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-5017","authenticated-orcid":false,"given":"James K.","family":"Rowlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"3762_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/00912174231166252","volume":"58","author":"DL Louie","year":"2023","unstructured":"Louie DL, Jegede OO, Hermes GL. Chronic use of benzodiazepines: the problem that persists. Int J Psychiatry Med. 2023;58:426\u201332.","journal-title":"Int J Psychiatry Med"},{"key":"3762_CR2","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91:1632\u20139.","journal-title":"Mayo Clin Proc"},{"key":"3762_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2019","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70:97\u2013106.","journal-title":"Psychiatr Serv"},{"key":"3762_CR4","doi-asserted-by":"publisher","first-page":"18m12174","DOI":"10.4088\/JCP.18m12174","volume":"79","author":"C Blanco","year":"2018","unstructured":"Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. J Clin Psychiatry. 2018;79:18m12174.","journal-title":"J Clin Psychiatry"},{"key":"3762_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1129447","volume":"14","author":"RK McHugh","year":"2023","unstructured":"McHugh RK, Votaw VR, Trapani EW, McCarthy MD. Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the national survey on drug use and health. Front Psychiatry. 2023;14:1129447.","journal-title":"Front Psychiatry"},{"key":"3762_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.drugalcdep.2018.04.028","volume":"189","author":"JW Welsh","year":"2018","unstructured":"Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O. Review: adjunctive pharmacological approaches for benzodiazepine tapers. Drug Alcohol Depend. 2018;189:96\u2013107.","journal-title":"Drug Alcohol Depend"},{"key":"3762_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/XEB.0000000000000161","volume":"17","author":"K Rowan-Robinson","year":"2019","unstructured":"Rowan-Robinson K. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Int J Evid Based Health. 2019;17:143\u20134.","journal-title":"Int J Evid Based Health"},{"key":"3762_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/ebmh.12.3.91","volume":"12","author":"CH Ashton","year":"2009","unstructured":"Ashton CH. Review: brief interventions, gradual dose reduction and psychological interventions increase benzodiazepine cessation compared with routine care. Evid Based Ment Health. 2009;12:91.","journal-title":"Evid Based Ment Health"},{"key":"3762_CR9","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.2174\/1381612821666150619092039","volume":"21","author":"P Sabioni","year":"2015","unstructured":"Sabioni P, Bertram J, Le Foll B. Off-label use of medications for treatment of benzodiazepine use disorder. Curr Pharm Des. 2015;21:3306\u201310.","journal-title":"Curr Pharm Des"},{"key":"3762_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.04.015","volume":"158","author":"CJ Jordan","year":"2019","unstructured":"Jordan CJ, Cao J, Newman AH, Xi ZX. Progress in agonist therapy for substance use disorders: lessons learned from methadone and buprenorphine. Neuropharmacology. 2019;158:107609.","journal-title":"Neuropharmacology"},{"key":"3762_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/jm051200u","volume":"49","author":"MG Russell","year":"2006","unstructured":"Russell MG, Carling RW, Street LJ, Hallett DJ, Goodacre S, Mezzogori E, et al. Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2\/3 subtype selective agonists for the treatment of anxiety. J Med Chem. 2006;49:1235\u20138.","journal-title":"J Med Chem"},{"key":"3762_CR12","first-page":"84","volume":"5","author":"TD Prevot","year":"2019","unstructured":"Prevot TD, Li G, Vidojevic A, Misquitta KA, Fee C, Santrac A, et al. Novel benzodiazepine-like ligands with various anxiolytic, antidepressant, or pro-cognitive profiles. Mol Neuropsychiatry. 2019;5:84\u201397.","journal-title":"Mol Neuropsychiatry"},{"key":"3762_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.24820\/ark.5550190.p011.398","volume":"2020","author":"KP Pandey","year":"2020","unstructured":"Pandey KP, Khan ZA, Golani LK, Mondal P, Mian Y, Rashid F, et al. Design, synthesis and characterization of novel gamma-aminobutyric acid type a receptor ligands. ARKIVOC. 2020;2020:242\u201356.","journal-title":"ARKIVOC"},{"key":"3762_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/0269881119882803","volume":"34","author":"Z Meng","year":"2020","unstructured":"Meng Z, Berro LF, Sawyer EK, R\u00fcedi-Bettschen D, Cook JE, Li G, et al. Evaluation of the anti-conflict, reinforcing, and sedative effects of YT-III-31, a ligand functionally selective for\u2009\u03b13 subunit-containing GABAA receptors. J Psychopharmacol. 2020;34:348\u201357.","journal-title":"J Psychopharmacol"},{"key":"3762_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1060949","volume":"13","author":"E Engin","year":"2023","unstructured":"Engin E. GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Front Psychiatry. 2023;13:1060949.","journal-title":"Front Psychiatry"},{"key":"3762_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrd3502","volume":"10","author":"U Rudolph","year":"2011","unstructured":"Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10:685\u201397.","journal-title":"Nat Rev Drug Discov"},{"key":"3762_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00213-013-2975-2","volume":"227","author":"BD Fischer","year":"2013","unstructured":"Fischer BD, Teixeira LP, van Linn ML, Namjoshi OA, Cook JM, Rowlett JK. Role of gamma-aminobutyric acid type a (GABAA) receptor subtypes in acute benzodiazepine physical dependence-like effects. Evidence from squirrel monkeys responding under a schedule of food presentation. Psychopharmacology. 2013;227:347\u201354.","journal-title":"Psychopharmacology"},{"key":"3762_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108985","volume":"228","author":"AN Duke","year":"2021","unstructured":"Duke AN, Tiruveedhula VVNPB, Sharmin D, Knutson DE, Cook JM, Platt DM, et al. Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABAA receptor subtypes. Drug Alcohol Depend. 2021;228:108985.","journal-title":"Drug Alcohol Depend"},{"key":"3762_CR19","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1021\/acs.jmedchem.9b01312","volume":"63","author":"S Maramai","year":"2020","unstructured":"Maramai S, Benchekroun M, Ward SE, Atack JR. Subtype selective \u03b3-aminobutyric acid type a receptor (GABAAR) modulators acting at the benzodiazepine binding site: An update. J Med Chem. 2020;63:3425\u201346.","journal-title":"J Med Chem"},{"key":"3762_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/0269881109354928","volume":"25","author":"JR Atack","year":"2010","unstructured":"Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Bohorquez SM, et al. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor \u03b12\/\u03b13 subtype-selective partial agonist. J Psychopharmacol. 2010;25:329\u201344.","journal-title":"J Psychopharmacol"},{"key":"3762_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/cne.903380303","volume":"338","author":"W Ma","year":"1993","unstructured":"Ma W, Saunders PA, Somogyi R, Poulter MO, Barker JK. Ontogeny of GABAA receptor subunit mRNAs in rat spinal cord and dorsal root ganglia. J Comp Neurol. 1993;338:337\u201359.","journal-title":"J Comp Neurol"},{"key":"3762_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature06493","volume":"451","author":"J Knabl","year":"2008","unstructured":"Knabl J, Witschi R, H\u00f6sl K, Reinold H, Zeilhofer UB, Ahmadi S, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 2008;451:330\u20134.","journal-title":"Nature"},{"key":"3762_CR23","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.2174\/156802611795371350","volume":"11","author":"JR Atack","year":"2011","unstructured":"Atack JR. GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11:1176\u2013202.","journal-title":"Curr Top Med Chem"},{"key":"3762_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/npp.2012.265","volume":"38","author":"NM Shinday","year":"2013","unstructured":"Shinday NM, Sawyer EK, Fischer BD, Platt DM, Licata SC, Atack JR, et al. Reinforcing effects of compounds lacking intrinsic efficacy at \u03b11 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys. Neuropsychopharmacology. 2013;38:1006\u201314.","journal-title":"Neuropsychopharmacology"},{"key":"3762_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1124\/jpet.118.249250","volume":"366","author":"AN Duke","year":"2018","unstructured":"Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, et al. Evidence that sedative effects of benzodiazepines involve unexpected GABAA receptor subtypes: quantitative observation studies in rhesus monkeys. J Pharm Exp Ther. 2018;366:145\u201357.","journal-title":"J Pharm Exp Ther"},{"key":"3762_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1124\/jpet.109.158303","volume":"332","author":"NA Ator","year":"2010","unstructured":"Ator NA, Atack JR, Hargreaves RJ, Burns HD, Dawson GR. Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at \u03b11 and \u03b12\/3 subtypes. J Pharm Exp Ther. 2010;332:4\u201316.","journal-title":"J Pharm Exp Ther"},{"key":"3762_CR27","first-page":"Unit 10.5","volume":"Chapter 10","author":"DM Platt","year":"2011","unstructured":"Platt DM, Carey G, Spealman RD. Models of neurological disease (substance abuse): Self-administration in monkeys. Curr Protoc Pharm. 2011;Chapter 10:Unit 10.5.","journal-title":"Curr Protoc Pharm"},{"key":"3762_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108076","volume":"213","author":"LF Berro","year":"2020","unstructured":"Berro LF, Rowlett JK. GABAA receptor subtypes and the reinforcing effects of benzodiazepines in remifentanil-experienced rhesus monkeys. Drug Alcohol Depend. 2020;213:108076.","journal-title":"Drug Alcohol Depend"},{"key":"3762_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2015.10.026","volume":"158","author":"BD Fischer","year":"2016","unstructured":"Fischer BD, Platt DM, Rallapalli SK, Namjoshi OA, Cook JM, Rowlett JK. Antagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis. Drug Alcohol Depend. 2016;158:22\u201329.","journal-title":"Drug Alcohol Depend"},{"key":"3762_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00213-005-0228-8","volume":"184","author":"JK Rowlett","year":"2006","unstructured":"Rowlett JK, Lelas S, Tornatzky W, Licata SL. Anti-conflict effects of benzodiazepines in rhesus monkeys: Relationship with therapeutic doses in humans and role of GABAA receptors. Psychopharmacology. 2006;184:201\u201311.","journal-title":"Psychopharmacology"},{"key":"3762_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1124\/jpet.105.094474","volume":"316","author":"NR Mirza","year":"2006","unstructured":"Mirza NR, Nielsen E\u00d8. Do subtype-selective gamma-aminobutyric acid a receptor modulators have a reduced propensity to induce physical dependence in mice?. J Pharm Exp Ther. 2006;316:1378\u201385.","journal-title":"J Pharm Exp Ther"},{"key":"3762_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002130050422","volume":"134","author":"RR Griffiths","year":"1997","unstructured":"Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology. 1997;134:1\u201337.","journal-title":"Psychopharmacology"},{"key":"3762_CR33","doi-asserted-by":"publisher","first-page":"e2348557","DOI":"10.1001\/jamanetworkopen.2023.48557","volume":"6","author":"DT Maust","year":"2023","unstructured":"Maust DT, Petzold K, Strominger J, Kim HM, Bohnert ASB. Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy. JAMA Netw Open. 2023;6:e2348557.","journal-title":"JAMA Netw Open"},{"key":"3762_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"key":"3762_CR35","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1080\/10826084.2025.2496936","volume":"60","author":"VR Votaw","year":"2025","unstructured":"Votaw VR, Trapani EW, Geyer RB, Sugarman DE, McHugh RK. A mixed-methods study of motives for benzodiazepine misuse among adults receiving substance use disorder treatment. Substance Use Misuse. 2025;60:1328\u201338.","journal-title":"Substance Use Misuse"},{"key":"3762_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2020.106752","volume":"114","author":"JJ Mahoney III","year":"2021","unstructured":"Mahoney III JJ, Winstanley EL, Lander LR, Berry JH, Marshalek PJ, Haut MW, et al. High prevalence of co-occurring substance use in individuals with opioid use disorder. Addict Behav. 2021;114:106752.","journal-title":"Addict Behav"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03762-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03762-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03762-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:03:50Z","timestamp":1768165430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03762-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3762"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03762-0","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JKR is founder and director of Impatia Therapeutics, LLC, which was established to provide funding mechanisms for drug development purposes. As of this writing, Impatia Therapeutics, LLC, has no ownership, licensing rights, or financial support associated with the studies presented in this manuscript. The use and data presented in this study are part of a patent: \u201cMethods for treating benzodiazepine misuse\/use disorder\u201d; Inventor: James Rowlett; Patent application UMMC Docket No. 19-1003 and published as US Patent Application No. 12,233,070 (Feb 25, 2025). Other authors of this paper declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}